Puma Biotechnology to Present at Cantor Fitzgerald Healthcare Conference
September 18 2017 - 4:20PM
Business Wire
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical
company, announced that Alan H. Auerbach, Chairman, Chief Executive
Officer, President and Founder of Puma, will provide an overview of
the Company, including recent developments, at 1:40 p.m. EDT on
Tuesday, September 26, at the Cantor Fitzgerald Global Healthcare
Conference. The conference will be held at the InterContinental New
York Barclay Hotel.
A live webcast of the presentation will be available on the
Company’s website at www.pumabiotechnology.com. The presentation will
be archived on the website and available for 30 days.
About Puma Biotechnology
Puma Biotechnology, Inc. is a biopharmaceutical company with a
focus on the development and commercialization of innovative
products to enhance cancer care. The Company in-licenses the global
development and commercialization rights to three drug candidates —
PB272 (neratinib (oral)), PB272 (neratinib (intravenous)) and
PB357. NERLYNX™ (neratinib) is approved for commercial use by
prescription in the United States as extended adjuvant therapy for
early stage HER2-positive breast cancer following adjuvant
trastuzumab-based therapy and is marketed as NERLYNX. Neratinib is
a potent irreversible tyrosine kinase inhibitor that blocks signal
transduction through the epidermal growth factor receptors, HER1,
HER2 and HER4. Currently, the Company is primarily focused on the
commercialization of NERLYNX and the continued development of its
other advanced drug candidates directed at the treatment of
HER2-positive breast cancer. The Company believes that NERLYNX has
clinical application in the potential treatment of several other
cancers that over-express or have a mutation in HER2.
Further information about Puma Biotechnology may be found at
www.pumabiotechnology.com.
Forward-Looking Statements
This press release and the webcast of the presentation contain
forward-looking statements, including statements regarding the
benefits of NERLYNX™ and neratinib, the Company’s clinical trials
and the announcement of data relative to those trials. All
forward-looking statements involve risks and uncertainties that
could cause the Company's actual results to differ materially from
the anticipated results and expectations expressed in these
forward-looking statements. These statements are based on current
expectations, forecasts and assumptions, and actual outcomes and
results could differ materially from these statements due to a
number of factors, which include, but are not limited to, the risk
factors disclosed in the periodic and current reports filed by the
Company with the Securities and Exchange Commission from time to
time, including the Company’s Quarterly Report on Form 10-Q for the
quarter ended June 30, 2017. Readers are cautioned not to place
undue reliance on these forward-looking statements, which speak
only as of the date hereof. The Company assumes no obligation to
update these forward-looking statements, except as required by
law.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170918006325/en/
Puma Biotechnology, Inc.Alan H. Auerbach or Mariann Ohanesian+1
424 248
6500info@pumabiotechnology.comir@pumabiotechnology.comorRusso
PartnersDavid Schull or Amiad Finkelthal+1 212 845
4200david.schull@russopartnersllc.comamiad.finkelthal@russopartnersllc.com
Puma Biotechnology (NASDAQ:PBYI)
Historical Stock Chart
From Aug 2024 to Sep 2024
Puma Biotechnology (NASDAQ:PBYI)
Historical Stock Chart
From Sep 2023 to Sep 2024